HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, Jian M Xu, Keun-Wook Lee, Shun-Chang Jiao, Jorge León Chong, Roberto I López-Sanchez, Timothy Price, Oleg Gladkov, Oliver Stoss, Julie Hill, Vivian Ng, Michaela Lehle, Marlene Thomas, Astrid Kiermaier, Josef Rüschoff, Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, Jian M Xu, Keun-Wook Lee, Shun-Chang Jiao, Jorge León Chong, Roberto I López-Sanchez, Timothy Price, Oleg Gladkov, Oliver Stoss, Julie Hill, Vivian Ng, Michaela Lehle, Marlene Thomas, Astrid Kiermaier, Josef Rüschoff

Abstract

Background: In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median overall survival by 2.7 months in patients with human epidermal growth factor receptor 2 (HER2)-positive [immunohistochemistry (IHC) 3+/fluorescence in situ hybridization-positive] gastric/gastroesophageal junction cancer compared with chemotherapy alone (hazard ratio 0.74). Post hoc exploratory analyses in patients expressing higher HER2 levels (IHC 2+/fluorescence in situ hybridization-positive or IHC 3+) demonstrated a 4.2-month improvement in median overall survival with trastuzumab (hazard ratio 0.65). The ToGA study provides the largest screening dataset available on HER2 overexpression/amplification in this indication. We further analyzed correlation(s) of HER2 overexpression/amplification with clinical and epidemiological factors.

Methods: HER2-positivity was analyzed by histological subtype, tumor location, geographic region, and specimen type. Exploratory efficacy analyses were performed.

Results: The HER2-positivity rate was 22.1 % across analyzed tumor samples. Rates were similar between European and Asian patients (23.6 % vs. 23.9 %), but higher in intestinal- vs. diffuse-type (31.8 % vs. 6.1 %), and gastroesophageal junction cancer versus gastric tumors (32.2 % vs. 21.4 %). Across all IHC scores, variability in HER2 staining (≤30 % stained cells) was observed in almost 50 % of cases, with increasing rates in lower IHC categories, and did not affect treatment outcome. The polysomy rate was 4 %.

Conclusions: HER2 expression varies by tumor location and type. All patients with advanced gastric or gastroesophageal junction cancer should be tested for HER2 status, preferably using IHC initially. Due to the unique characteristics of gastric cancer, specific testing/scoring guidelines should be adhered to.

Trial registration: ClinicalTrials.gov NCT01041404.

References

    1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712. doi: 10.1126/science.2470152.
    1. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–1529. doi: 10.1093/annonc/mdn169.
    1. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726. doi: 10.1200/JCO.20.3.719.
    1. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805. doi: 10.1111/j.1365-2559.2008.03028.x.
    1. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51:1371–1379. doi: 10.1007/s10620-005-9057-1.
    1. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273–278. doi: 10.1093/annonc/mdi064.
    1. Takehana T, Kunimoto K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002;98:833–837. doi: 10.1002/ijc.10257.
    1. Aoyagi K, Kohfuji K, Yano S, Murakami N, Miyagi M, Takeda J. Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading type and penetrating-type gastric carcinoma. Kurume Med J. 2001;48:197–200. doi: 10.2739/kurumemedj.48.197.
    1. Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ. Prognostic factors in gastric cancer. Mod Pathol. 1998;11:870–877.
    1. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, Da Costa WL, Jr, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 2011;29:3030–3036. doi: 10.1200/JCO.2010.33.6313.
    1. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012;18:546–554. doi: 10.1158/1078-0432.CCR-11-2272.
    1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. doi: 10.1016/S0140-6736(10)61121-X.
    1. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
    1. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637–650. doi: 10.1038/modpathol.2011.198.
    1. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2000;71:127–164. doi: 10.1016/j.critrevonc.2009.01.004.
    1. Waddell T, Verheij M, Allum W, et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi57–63.
    1. Kang Y, Bang Y, Lordick F, Park SR, Sawaki A, Chung HC, et al. Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity. 2008; American Society of Clinical Oncology Gastrointestinal Cancers Symposium (Orlando, FL, USA, 25–27 January): Abstract 11.
    1. Shah M, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17:2693–2701. doi: 10.1158/1078-0432.CCR-10-2203.
    1. Rüschoff J. Adenocarcinoma of the GEJ: gastric or oesophageal cancer? Recent Results Cancer Res. 2012;196:107–113. doi: 10.1007/978-3-642-31629-6_7.
    1. Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU. et al [Her2 testing in gastric cancer. What is different in comparison to breast cancer?] Pathologe. 2010;31:208–217. doi: 10.1007/s00292-010-1278-1.
    1. Möhler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D. et al [German S3-guideline “Diagnosis and treatment of esophagogastric cancer”] Z Gastroenterol. 2011;49:461–531. doi: 10.1055/s-0031-1273201.
    1. Powell WC, Zielinski D, Ranger-Moore J, Nagelmeier I, Stoss O, Ruschoff J, et al. Determining the HER2 status in gastric cancer: A method comparison study of two patient cohorts. 2010; American Society of Clinical Oncology Gastrointestinal Cancers Symposium (Orlando, FL, USA, 22–24 January): Abstract 17.
    1. van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res. 2007;9:R68. doi: 10.1186/bcr1776.
    1. Hanna WM, Kwok K. Chromogenic in situ hybridization: a viable alternative to fluorescence in situ hybridization in the HER2 testing algorithm. Mod Pathol. 2006;19:481–487. doi: 10.1038/modpathol.3800555.
    1. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002;15:657–665. doi: 10.1038/modpathol.3880582.
    1. Dietel M, Ellis IO, Höfler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007;451:19–25. doi: 10.1007/s00428-007-0424-5.
    1. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299–307. doi: 10.1007/s00428-010-0952-2.
    1. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–673. doi: 10.1093/annonc/mdn717.
    1. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46. doi: 10.1056/NEJMoa073149.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅